Breaking Finance News

Zacks Investment Research downgraded Oxford Immunotec Global PLC (NASDAQ:OXFD) to Sell in a report released today.

Zacks Investment Research has downgraded Oxford Immunotec Global PLC (NASDAQ:OXFD) to Sell in a report released on Thursday January 12, 2017.

Just yesterday Oxford Immunotec Global PLC (NASDAQ:OXFD) traded -1.03% lower at $14.43. Oxford Immunotec Global PLC’s 50-day moving average is $14.79 and its 200-day moving average is $11.92. The last stock price is up 21.02% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.05% over the same time period. 0 shares of OXFD traded hands, down from an average trading volume of 67,784

Recent Performance Chart

Oxford Immunotec Global PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC has 52 week low of $7.73 and a 52 week high of $15.76 and has a market capitalization of $0.

Brief Synopsis On Oxford Immunotec Global PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company's T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company's autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient's cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *